Abgenix to Host Fourth Quarter and Full Year 2005 Conference Call
14 Februar 2006 - 2:30PM
PR Newswire (US)
FREMONT, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Abgenix, Inc.
(NASDAQ:ABGX) will announce financial results for the fourth
quarter and full year of 2005 on Tuesday, February 21, 2006, after
the close of financial markets. Following the announcement, Abgenix
will host a conference call at 1:30 p.m. Pacific Time that
afternoon to review the company's financial results. The live and
archived webcasts of the conference call will be available on the
Abgenix website, http://www.abgenix.com/. To participate in the
conference call, please dial 800-591-6944 fifteen minutes before
the conference begins. International callers should dial
617-614-4910. The pass code is 82136361. A telephonic replay of the
call will be available by dialing 888-286-8010. International
callers should dial 617-801-6888. The replay participant code is
66896648. About Abgenix Abgenix is a biopharmaceutical company
focused on the discovery, development and manufacturing of human
therapeutic antibodies. The company's antibody development platform
includes a leading technology and state-of-the-art manufacturing
capabilities that enable the rapid generation, selection and
production of high affinity, fully human antibody product
candidates to a variety of disease targets. Abgenix leverages its
leadership position in human antibody technology to build a
diversified product portfolio through the establishment of
collaborations with multiple pharmaceutical and biotechnology
companies. For more information on Abgenix, visit the company's
website at http://www.abgenix.com/. DATASOURCE: Abgenix, Inc.
CONTACT: Greg Mann, Director of Corporate Communications &
Investor Relations of Abgenix, +1-510-284-6566 Web site:
http://www.abgenix.com/
Copyright
Abgenix (NASDAQ:ABGX)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Abgenix (NASDAQ:ABGX)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Abgenix (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Abgenix (MM) News-Artikel